Arthneeti
Latest: Torrent Pharmaceuticals Ltd Q2 FY27 (Jul–Sep 2026) results →This page is Q2 FY26 (Jul–Sep 2025).All Q2 FY26 results →
TP

Torrent Pharmaceuticals Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Torrent Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹4,896
Market cap₹1.8L Cr
P/E82.4
Updated23 Aug 2026
Read5 min read

The short version

India business is expected to continue outperforming market growth, driven by chronic therapies, new launches, and improved field force productivity. India business expected to continue outperforming market growth with focus on chronic therapies and new launches driving volume growth. - Brazil showing strong double-digit constant currency growth with healthy volume growth and mid-single digit price increases. - US business optimistic on ramping up filings (4-5 this year, aiming for 10 next year, 15 thereafter) with intent to return to sustainable profitability, but no large new CAPEX planned. - Germany facing supply disruption; expected normalization by Q4 FY'26; growth guidance currently withheld. - Overall revenue growth for Q2 FY'26 was 14%, with Operating EBITDA up 15% and margin at 32.8%. - Leverage is low at 0.45x net debt to EBITDA. - CAPEX expected at Rs.

From Torrent Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • India business is expected to continue outperforming market growth, driven by chronic therapies, new launches, and improved field force productivity.
  • India Q2 volume growth was 3.7% versus 0% market growth; price growth at 5.5%, indicating sustained demand.
  • Brazil is showing strong growth (15% vs market 7%) supported by new product launches and volume pickups in existing mega brands.
  • The semaglutide opportunity in Brazil is regarded as very significant, with filings under priority review.
  • US business is ramping up ANDA filings (4-5 this year, up to 15 in subsequent years), aiming to return to profitability without major CAPEX.
  • Germany growth is currently impacted by supplier disruption; normalization expected from Q4.
  • Field force expansions ongoing: India aims for 7,000 reps by FY end, supporting volume growth.

2 more points from Torrent Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Torrent Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • For H1 FY'26, total CAPEX was roughly Rs. 200 crores.
  • Full year CAPEX for FY'26 is expected to be around Rs. 300 crores.
  • Over the next three years, average annual CAPEX is projected to be between Rs. 250 to 300 crores.
  • No large CAPEX investments planned in the US generics space; current infrastructure supports upcoming product launches.
  • Future expansions primarily in chronic and sub-chronic divisions in India with field force growth.

2 more points from Torrent Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Torrent Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Key points related to business outlook include: - India business showing robust growth with expanding field force and new therapy launches. - Brazil business with strong growth and a rich pipeline of 65 molecules filed awaiting ANVISA approval. - US generic filings ramping up from 4-5 ANDAs currently to around 10 next year and eventually up to 15. - Semaglutide filings underway in Brazil, awaiting approval; expected to be a material opportunity when launched.

2 more points from Torrent Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

Torrent Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹5.0K Cr, net profit ₹534 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Torrent Pharma.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Laurus Labs

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Torrent Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Torrent Pharmaceuticals Ltd Q2 FY26 results?

India business is expected to continue outperforming market growth, driven by chronic therapies, new launches, and improved field force productivity. India business expected to continue outperforming market growth with focus on chronic therapies and new launches driving volume growth. - Brazil showing strong double-digit constant currency growth with healthy volume growth and mid-single digit price increases. - US business optimistic on ramping up filings (4-5 this year, aiming for 10 next year, 15 thereafter) with intent to return to sustainable profitability, but no large new CAPEX planned. - Germany facing supply disruption; expected normalization by Q4 FY'26; growth guidance currently withheld. - Overall revenue growth for Q2 FY'26 was 14%, with Operating EBITDA up 15% and margin at 32.8%. - Leverage is low at 0.45x net debt to EBITDA. - CAPEX expected at Rs.

What is Torrent Pharmaceuticals Ltd share price analysis?

Torrent Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 82.4 with a market cap of ₹183,832 Cr. Investors should review the full earnings analysis for detailed insights.

Is Torrent Pharmaceuticals Ltd planning capital expenditure?

For H1 FY'26, total CAPEX was roughly Rs.

Keep Torrent Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.